# AK129 Combination Therapy for Advanced Solid Tumors

Source: https://onco.cc/trials/nct06943820/  
OnCo record `nct06943820` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.

## Summary

AK129 Combination Therapy for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06943820 by Akeso, with 230 participants planned, started 2025-05-21 and due to reach its primary completion in 2026-12. Interventions recorded: AK129(dose 1), Pemetrexed, Paclitaxel, Carboplatin, AK129(dose 2). Conditions listed: Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06943820
- Phase: 1/2
- Setting: A Phase Ib/II Study of Anti-PD-1/LAG-3 Bispecific Antibody AK129 Combinations in Advanced Solid Tumors
- Sponsor: Akeso
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT06943820: https://clinicaltrials.gov/study/NCT06943820

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06943820.json